(Q38024158)

27 August 2017

title

The cost-effectiveness of immunotherapy for respiratory allergy: a review (English)

1 reference

27 August 2017

1 reference

1 reference

S Simoens

1

1 reference

27 August 2017

publication date

5 July 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

67

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

1087-1105

1 reference

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

The economic impact of allergic rhinitis and current guidelines for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Allergic rhinitis and the common cold--high cost to society

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Specific immunotherapy by the sublingual route for respiratory allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Immunotherapy for allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Ragweed immunotherapy in adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Economic evaluation of sublingual vs subcutaneous allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Economic studies of immunotherapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

The economic burden of allergic rhinitis: a critical evaluation of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Allergic rhinitis and impairment issues in schoolchildren: a consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

The work impact of asthma and rhinitis: findings from a population-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Review of NICE's recommendations, 1999-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

Design and Recruitment for the GAP Trial, Investigating the Preventive Effect on Asthma Development of an SQ-Standardized Grass Allergy Immunotherapy Tablet in Children with Grass Pollen–Induced Allergic Rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02861.X

10.1111/J.1398-9995.2012.02861.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference